Results for in utero translation from English to Maltese

mitochondrial dysfunction following exposure in utero
disfunzjoni mitokondrija wara esponiment in utero

vaccine breakthrough infection (after in utero exposure to
infezzjoni kkawżata mit-tilqima nnifisha (wara espożizzjoni in

vaccine breakthrough infection (after in utero exposure to infliximab)*.
infezzjoni kkawżata mit-tilqima nnifisha (wara espożizzjoni in utero għal infliximab)*.

exposure in utero to obinutuzumab and vaccination of infants with live virus vaccines
esponiment in utero għal obinutuzumab u tilqim ta’ trabi b’vaċċini b’virus ħaj

rat offspring exposed to telaprevir in utero showed normal body weight at birth.
frieħ tal-firien esposti għal telaprevir fil- ġuf urew piż normali tal-ġisem fit-twelid.

patients exposed only to antiretrovirals in utero or intrapartum were considered treatment-naive.
il- pazjenti esposti għal antiretrovirali in utero jew intrapartum kienu kkunsidrati bħala li qatt ma kienu kkurati fil-passat.

developmental toxicity studies performed in cynomolgus monkeys revealed no evidence of embryotoxicity in utero.
37 studji dwar l- effett tossiku fuq l- iżvilupp li twettqu fuq xadini cynomolgus ma żvelaw l- ebda evidenza ta ’ effett tossiku fuq l- embriju in utero.

in utero exposure to the active moiety isavuconazole had no effect on the fertility of the surviving pups.
esponiment in utero tal-porzjon attiv isavuconazole ma kellux effett fuq il-fertilità tal-frieħ sopravissuti.

in these studies, maternal antibodies to recombinant human hyaluronidase were transferred to offspring in utero.
f’dawn l-istudji, l-antikorpi materni għal hyaluronidase uman rikombinanti ġew ittrasferiti lit-tarbija fil-ġuf.

any child exposed in utero to nucleoside and nucleotide analogues, even hiv-negative children, should
kull tarbija esposta in utero għall - analogi tan- nuklejosidi u tan- nukleotidi, anke trabi li huma negattivi għall- hiv, għandhom jiġu segwiti klinikament u f’ testijiet tal- laboratorju u jridu jiġu investigati kompletament għall- possibiltà ta ’ disfunzjoni tal- mitokondrija f’ każ ta ’ sinjali jew sintomi relevanti.

the risk of disseminated bcg infection after bcg vaccination of infants up to 6 months of age who were exposed in utero to infliximab.
ir-riskju ta’ infezzjoni bcg mifruxa wara t-tilqima kontra bcg ta’ trabi li jkollhom sa 6 xhur li kienu esposti fl-utru għal infliximab.

additionally, developmental external or visceral abnormalities were identified in the urogenital system of 2 infants exposed in utero to ipilimumab.
barra minn hekk, kienu identifikati abnormalitajiet esterni jew vixxerali tal-iżvilupp fis-sistema uroġenitali ta’ 2 trabi esposti in utero għal ipilimumab.

both hypoglycaemia and hyperglycaemia, which can occur in inadequately controlled diabetes therapy, increase the risk of malformations and death in utero.
kemm l-ipogliċemija kif ukoll l-ipergliċemija, li jistgħu jseħħu f’terapija fejn id-dijabete ma tkunx ikkontrollata b’mod adegwat, iżidu r-riskju ta’ malformazzjonijiet u mewt in utero.

to care for and assist the mother during labour and to monitor the condition of the foetus in utero by the appropriate clinical and technical means;
li jieħdu ħsieb u jassistu lill-omm waqt il-ħlas u li jagħmlu monitoraġġ tal-kondizzjoni tal-fetu fl-utru bil-mezzi kliniċi u tekniċi approprjati;

administration of live vaccines to infants exposed to abatacept in utero is not recommended for 14 weeks following the mother’s last exposure to abatacept during pregnancy.
l-għoti ta’ vaċċini ħajjin lil trabi esposti għal abatacept in utero mhuwiex rakkomandat għal 14-il ġimgħa wara l-aħħar espożizzjoni tal-omm għal abatacept waqt it-tqala.

there have been reports of mitochondrial dysfunction in hiv-negative infants exposed in utero and/ or post-natally to nucleoside analogues.
kien hemm rapporti ta ’ każi ta 'funzjonament mitokondrjali ħażin fi trabi negattivi għall- hiv, li kienu esposti, in utero u/ jew wara t- twelid, għal analogi tan- nukleosidi.

in case of in utero exposure, monitoring of the newborn for the potential adverse events of tacrolimus is recommended (in particular effects on the kidneys).
f’każ ta’ espożizzjoni in utero, monitoraġġ tat- tarbija mwielda għal xi effetti avversi potenzjali ta’ tacrolimus huwa rakkomandat (speċjalment effetti fuq il-kliewi ).

in case of in utero exposure, monitoring of the newborn for potential adverse events of tacrolimus is recommended (in particular, effects on the kidneys).
f’każ ta’ esponiment in utero, huwa rrakkomandat monitoraġġ tat-tarbija tat-twelid għall- avvenimenti avversi potenzjali ta’ tacrolimus (b’mod partikolari, effetti fuq il-kliewi).

at least a six month waiting period following birth is recommended before the administration of live vaccines to infants exposed in utero to infliximab (see section 4.6).
huwa rakkomandat perjodu ta’ mill-inqas sitt xhur wara t-twelid qabel l-għoti ta’ tilqim ħaj lil trabi esposti in utero għal infliximab (ara sezzjoni 4.6).

rare: agranulocytosis (including infants exposed in utero to infliximab), thrombotic thrombocytopenic purpura, pancytopenia, haemolytic anaemia, idiopathic thrombocytopenic purpura.
rari: agranuloċitożi (inkluż trabi esposti in utero għal infliximab), purpura trombotika tromboċitopenika, panċitopenija, anemija emolitika, purpura tromboċitopenika idjopatika.